<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100125</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH_ENDO2</org_study_id>
    <nct_id>NCT01100125</nct_id>
  </id_info>
  <brief_title>Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment</brief_title>
  <official_title>Comparison Between Sitagliptin Add-on Therapy and Insulin Dose Increase Therapy for Uncontrolled Type 2 Diabetes on Insulin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well established that inhibition of dipeptidyl peptidase (DPP)-IV reduces glucose
      levels and preserves pancreatic beta cell function in patients with type 2 diabetes. DPP-IV
      inhibitors stimulate insulin secretion as well as insulin biosynthesis and inhibit glucagon
      secretion from pancreas by increasing incretin (GLP-1) levels. Recent studies reported that
      combination therapy with DPP-IV inhibitors and other oral antidiabetic medication have
      additive or synergistic effects in lowering glycose level, preserving beta-cell mass and
      function as well as enhancing insulin sensitivity. However, there have been few studies about
      the glucose lowering effect of DPP-IV inhibitors in patients with type 2 diabetes on insulin
      treatment.

      The researchers hypothesized that DPP-IV inhibitor add-on therapy to insulin treatment may
      have favorable effects on glucose control and endogenous insulin secretory function in type 2
      diabetic patients. The researchers plan to compare between sitagliptin (DPP-IV inhibitor)
      add-on therapy and insulin dose increase therapy in uncontrolled type 2 diabetes on insulin
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of HbA1C</measure>
    <time_frame>24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the number of patients in HbA1C &lt;7% without hypoglycemia</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypoglycemia(symptoms consistent with hypoglycemia and confirmed by plasma glucose &lt; 72 mg/dL)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of C-peptide</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of body weight and waist circumference</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of insulin dose</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin dose increase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>sitagliptin 100mg once daily, orally, for 24 weeks.</description>
    <arm_group_label>sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin dose increase</intervention_name>
    <description>insulin dose increase</description>
    <arm_group_label>insulin dose increase</arm_group_label>
    <other_name>Long acting insulin (Lantus)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  HbA1c ≥ 7%

          -  Age ≥ 18

          -  Insulin treatment with or without oral antidiabetic medication

        Exclusion Criteria:

          -  Contraindication to sitagliptin

          -  Pregnant or breast feeding women

          -  Type 1 diabetes, gestational diabetes, or diabetes with secondary cause

          -  Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT &gt;
             3-fold the upper limit of normal)

          -  Renal failure (Cr &gt; 2.0)

          -  Cancer within 5 years

          -  Not appropriate for oral antidiabetic agent

          -  Medication which affect glycemic control

          -  Disease which affect efficacy and safety of drugs

          -  Other clinical trial within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2010</study_first_submitted>
  <study_first_submitted_qc>April 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2010</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Assisstant Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Sitagliptin</keyword>
  <keyword>insulin</keyword>
  <keyword>C-peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

